Checkpoint Inhibitors and Classical Hodgkin’s Lymphoma: Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Tumor (Experience at the NI Pirogov Russian National Medical Center of Surgery)

Background. Checkpoint inhibitors contribute to improving the treatment outcomes in patients with relapsed/refractory classical Hodgkin’s lymphoma (cHL). The paper describes the first generalized experience with pembrolizumab-inducing cHL immunotherapy in Russia. The hallmark of the study is a long...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Vladislav Olegovich Sarzhevskii, E. A. Demina, N. E. Mochkin, A. A. Spornik, A. A. Mamedova, E. G. Smirnova, A. E. Bannikova, A. A. Samoilova, V. S. Bogatyrev, V. Ya. Melnichenko
Natura:	Artigo
Lingua:	Russo
Pubblicazione:	Practical Medicine Publishing House 2021-01-01
Serie:	Клиническая онкогематология
Soggetti:	сheckpoint inhibitors immunotherapy classical hodgkin’s lymphoma pembrolizumab
Accesso online:	https://bloodjournal.ru/index.php/coh/article/view/170
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!